Skip to main content

Transdermal Contraceptive Delivery Systems

  • Chapter
  • 1869 Accesses

Part of the Current Clinical Practice book series (CCP)

Abstract

The transdermal contraceptive system (TDS or patch) is a highly effective, reversible method delivering either estrogen and progestin or progestin alone similar to oral contraceptives (OCs). The marketed TDS contains both ethinyl estradiol and norelgestromin (EE/NGM, Ortho Evra, Janssen Pharmaceuticals), and was approved by the US FDA in 2001. The EE/NGM delivers the hormones over a 1 week period of time and is indicated for the prevention of pregnancy. Besides having many of the same contraceptive and non-contraceptive benefits as combination oral contraceptives (COCs) containing both estrogen and progestogen, transdermal contraception has additional advantages such as lower peak serum concentrations after application, avoidance of first-pass hepatic metabolism, and a less frequent administration schedule resulting in increased compliance. The most common adverse events are application site reactions, breast discomfort, nausea, and headache. There are new TDS under development that result in lower serum levels of ethinyl estradiol and progestin and others delivering a progestin only.

Keywords

  • Transdermal contraceptive system
  • Contraceptive patch
  • Reversible contraceptive method
  • Estrogen
  • Progestin
  • Oral contraceptives
  • Venous thromboembolism

This is a preview of subscription content, access via your institution.

Buying options

Chapter
USD   29.95
Price excludes VAT (USA)
  • DOI: 10.1007/978-3-319-20185-6_6
  • Chapter length: 19 pages
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
eBook
USD   119.00
Price excludes VAT (USA)
  • ISBN: 978-3-319-20185-6
  • Instant PDF download
  • Readable on all devices
  • Own it forever
  • Exclusive offer for individuals only
  • Tax calculation will be finalised during checkout
Fig. 6.1

References

  1. Abrams LS, Skee D, Natarajan J, Wong FA. Pharmacokinetic overview of Ortho Evra/Evra. Fertil Steril. 2002;77(2 Suppl 2):S3–12.

    CrossRef  PubMed  Google Scholar 

  2. van den Heuvel MW, van Bragt AJ, Alnabawy AK, Kaptein MC. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal patch and an oral contraceptive. Contraception. 2005;72(3):168–74.

    CrossRef  PubMed  Google Scholar 

  3. Devineni D, Skee D, Vaccaro N, Massarella J, Janssens L, LaGuardia KD, et al. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. J Clin Pharmacol. 2007;47(4):497–509.

    CAS  CrossRef  PubMed  Google Scholar 

  4. White T, Jain JK, Stanczyk FZ. Effect of oral versus transdermal steroidal contraceptives on androgenic markers. Am J Obstet Gynecol. 2005;192(6):2055–9.

    CAS  CrossRef  PubMed  Google Scholar 

  5. Stanczyk FZ, Rubin A, Flood L, Foegh M. Pharmacokinetics, tolerability and cycle control of three transdermal contraceptive delivery systems containing different doses of ethinyl estradiol and levonorgestrel. Horm Mol Biol Clin Investig. 2011;6:231–40.

    CAS  PubMed  Google Scholar 

  6. Archer DF, Stanczyk FZ, Rubin A, Foegh M. Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. Contraception. 2012;85(6):595–601.

    CAS  CrossRef  PubMed  Google Scholar 

  7. Zieman M, Guillebaud J, Weisberg E, Shangold GA, Fisher AC, Creasy GW. Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertil Steril. 2002;77(2 Suppl 2):S13–8.

    CrossRef  PubMed  Google Scholar 

  8. Foegh M, Archer DF, Stanczyk FZ, Rubin A, Mishell Jr DR. Ovarian activity in obese and nonobese women treated with three transdermal contraceptive patches delivering three different doses of ethinyl estradiol and levonorgestrel. Contraception. 2013;87(2):201–11.

    CAS  CrossRef  PubMed  Google Scholar 

  9. Stanczyk FZ, Archer DF, Rubin A, Foegh M. Therapeutically equivalent pharmacokinetic profile across three application sites for AG200-15, a novel low-estrogen dose contraceptive patch. Contraception. 2013;87(6):744–9.

    CAS  CrossRef  PubMed  Google Scholar 

  10. Archer DF, Stanczyk FZ, Rubin A, Foegh M. Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise. Contraception. 2013;87(2):212–9.

    CAS  CrossRef  PubMed  Google Scholar 

  11. Kaunitz AM, Portman D, Westhoff CL, Archer DF, Mishell Jr DR, Rubin A, et al. Low-dose levonorgestrel and ethinyl estradiol patch and pill: a randomized controlled trial. Obstet Gynecol. 2014;123(2 Pt 1):295–303.

    CAS  CrossRef  PubMed  Google Scholar 

  12. Available from: http://www.clinicaltrials.gov/ct2/show/NCT02158572?term=agile+transdermal+contraceptive&rank=3

  13. Heger-Mahn D, Warlimont C, Faustmann T, Gerlinger C, Klipping C. Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition, acceptability and safety over two cycles in female volunteers. Eur J Contracept Reprod Health Care. 2004;9(3):173–81.

    CAS  CrossRef  PubMed  Google Scholar 

  14. Junge W, Heger-Mahn D, Trummer D, Merz M. Investigation of the hemostatic effect of a transdermal patch containing 0.55 mg ethinyl estradiol and 2.1 mg gestodene compared with a monophasic oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel: an open-label, randomized, crossover study. Drugs R&D. 2013;13(3):223–33.

    CAS  CrossRef  Google Scholar 

  15. Wiegratz I, Bassol S, Weisberg E, Mellinger U, Merz M. Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study. Reproductive sciences. 2014;21(12):1518–25.

    CAS  CrossRef  PubMed  Google Scholar 

  16. Lidegaard O, Nielsen LH, Skovlund CW, Lokkegaard E. Venous thrombosis in users of non-oral hormonal contraception: follow-up study, Denmark 2001–10. BMJ. 2012;344:e2990.

    PubMed Central  CrossRef  PubMed  Google Scholar 

  17. Sachdeva V, Bai Y, Kydonieus A, Banga AK. Formulation and optimization of desogestrel transdermal contraceptive patch using crystallization studies. Int J Pharm. 2013;441(1–2):9–18.

    CAS  CrossRef  PubMed  Google Scholar 

  18. Bahamondes L, Bahamondes MV. New and emerging contraceptives: a state-of-the-art review. Int J Womens Health. 2014;6:221–34.

    PubMed Central  CrossRef  PubMed  Google Scholar 

  19. Lopez LM, Grimes DA, Chen M, Otterness C, Westhoff C, Edelman A, et al. Hormonal contraceptives for contraception in overweight or obese women. Cochrane Database Syst Rev. 2013;4, CD008452.

    PubMed  Google Scholar 

  20. Archer DF, Cullins V, Creasy GW, Fisher AC. The impact of improved compliance with a weekly contraceptive transdermal system (Ortho Evra) on contraceptive efficacy. Contraception. 2004;69(3):189–95.

    CAS  CrossRef  PubMed  Google Scholar 

  21. Archer DF, Bigrigg A, Smallwood GH, Shangold GA, Creasy GW, Fisher AC. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertil Steril. 2002;77(2 Suppl 2):S27–31.

    CrossRef  PubMed  Google Scholar 

  22. Hooper DJ. Attitudes, awareness, compliance and preferences among hormonal contraception users: a global, cross-sectional, self-administered, online survey. Clin Drug Investig. 2010;30(11):749–63.

    CrossRef  PubMed  Google Scholar 

  23. Lopez LM, Grimes DA, Gallo MF, Stockton LL, Schulz KF. Skin patch and vaginal ring versus combined oral contraceptives for contraception. Cochrane Database Syst Rev. 2013;4, CD003552.

    PubMed  Google Scholar 

  24. Pierson RA, Archer DF, Moreau M, Shangold GA, Fisher AC, Creasy GW. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertil Steril. 2003;80(1):34–42.

    CrossRef  PubMed  Google Scholar 

  25. Anderson FD. Selectivity and minimal androgenicity of norgestimate in monophasic and triphasic oral contraceptives. Acta Obstet Gynecol Scand Suppl. 1992;156:15–21.

    CAS  CrossRef  PubMed  Google Scholar 

  26. Sibai BM, Odlind V, Meador ML, Shangold GA, Fisher AC, Creasy GW. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertil Steril. 2002;77(2 Suppl 2):S19–26.

    CrossRef  PubMed  Google Scholar 

  27. Smallwood GH, Meador ML, Lenihan JP, Shangold GA, Fisher AC, Creasy GW, et al. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol. 2001;98(5 Pt 1):799–805.

    CAS  CrossRef  PubMed  Google Scholar 

  28. Jick S, Kaye JA, Li L, Jick H. Further results on the risk of nonfatal venous thromboembolism in users of the contraceptive transdermal patch compared to users of oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol. Contraception. 2007;76(1):4–7.

    CAS  CrossRef  PubMed  Google Scholar 

  29. Jick SS, Kaye JA, Russmann S, Jick H. Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrel. Contraception. 2006;73(6):566–70.

    CAS  CrossRef  PubMed  Google Scholar 

  30. Jick SS, Hagberg KW, Kaye JA. ORTHO EVRA and venous thromboembolism: an update. Contraception. 2010;81(5):452–3.

    CrossRef  PubMed  Google Scholar 

  31. Jick SS, Hagberg KW, Hernandez RK, Kaye JA. Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolism. Contraception. 2010;81(1):16–21.

    CAS  CrossRef  PubMed  Google Scholar 

  32. Cole JA, Norman H, Doherty M, Walker AM. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. Obstet Gynecol. 2007;109(2 Pt 1):339–46.

    CrossRef  PubMed  Google Scholar 

  33. Dore DD, Norman H, Loughlin J, Seeger JD. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. Contraception. 2010;81(5):408–13.

    CAS  CrossRef  PubMed  Google Scholar 

  34. Burkman RT. Transdermal hormonal contraception: benefits and risks. Am J Obstet Gynecol. 2007;197(2):1341–6.

    CrossRef  Google Scholar 

  35. Heit JA, Kobbervig CE, James AH, Petterson TM, Bailey KR, Melton III LJ. Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study. Ann Intern Med. 2005;143(10):697–706.

    CrossRef  PubMed  Google Scholar 

  36. Jick SS, Jick H. The contraceptive patch in relation to ischemic stroke and acute myocardial infarction. Pharmacotherapy. 2007;27(2):218–20.

    CrossRef  PubMed  Google Scholar 

  37. Audet MC, Moreau M, Koltun WD, Waldbaum AS, Shangold G, Fisher AC, et al. Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs. an oral contraceptive: a randomized controlled trial. JAMA. 2001;285(18):2347–54.

    CAS  CrossRef  PubMed  Google Scholar 

  38. Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet. 1990;18(6):472–84.

    CAS  CrossRef  PubMed  Google Scholar 

  39. Back DJ, Breckenridge AM, Crawford FE, Hall JM, MacIver M, Orme ML, et al. The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. Contraception. 1980;21(2):135–43.

    CAS  CrossRef  PubMed  Google Scholar 

  40. Division of Reproductive Health NCfCDP, Health Promotion CfDC, Prevention. U.S. selected practice recommendations for contraceptive use, 2013: adapted from the World Health Organization selected practice recommendations for contraceptive use, 2nd edition. MMWR Recommendations and reports. 2013;62(RR-05):1–60.

    Google Scholar 

  41. Medical Eligibility Criteria for Contraceptive Use: A WHO Family Planning Cornerstone. WHO Guidelines Approved by the Guidelines Review Committee. 4th ed. Geneva: WHO; 2010.

    Google Scholar 

  42. Ortho Evra [Internet]. [cited April 2014]. Available from: www.orthoevra.com

  43. Zacur HA, Hedon B, Mansour D, Shangold GA, Fisher AC, Creasy GW. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertil Steril. 2002;77(2 Suppl 2):S32–5.

    CrossRef  PubMed  Google Scholar 

  44. Stewart FH, Kaunitz AM, Laguardia KD, Karvois DL, Fisher AC, Friedman AJ. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstet Gynecol. 2005;105(6):1389–96.

    CAS  CrossRef  PubMed  Google Scholar 

  45. Centers for Disease Control and Prevention. Update to CDC’s U.S. medical eligibility criteria for contraceptive use, 2010: revised recommendations for the use of contraceptive methods during the postpartum period. MMWR Morb Mortal Wkly Rep. 2011;60(26):878–83.

    Google Scholar 

  46. Espey E, Ogburn T, Leeman L, Singh R, Ostrom K, Schrader R. Effect of progestin compared with combined oral contraceptive pills on lactation: a randomized controlled trial. Obstet Gynecol. 2012;119(1):5–13.

    PubMed Central  CAS  CrossRef  PubMed  Google Scholar 

  47. Hedon B, Helmerhorst FM, Cronje HS, Shangold G, et al. Comparison of efficacy, cycle control, compliance, and safety in users of a contraceptive patch versus an oral contraceptive. BJOG. 2000;70:78.

    Google Scholar 

  48. Mishell Jr DR, Kletzky OA, Brenner PF, Roy S, Nicoloff J. The effect of contraceptive steroids on hypothalamic-pituitary function. Am J Obstet Gynecol. 1977;128(1):60–74.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Intira Sriprasert MD .

Editor information

Editors and Affiliations

Rights and permissions

Reprints and Permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Sriprasert, I., Archer, D.F. (2016). Transdermal Contraceptive Delivery Systems. In: Shoupe, D., Mishell, Jr., D. (eds) The Handbook of Contraception. Current Clinical Practice. Humana Press, Cham. https://doi.org/10.1007/978-3-319-20185-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-20185-6_6

  • Publisher Name: Humana Press, Cham

  • Print ISBN: 978-3-319-20184-9

  • Online ISBN: 978-3-319-20185-6

  • eBook Packages: MedicineMedicine (R0)